Date: 2013-05-21
Type of information: Development agreement
Compound: point-of-care genetic tests
Company: QuantuMDx (UK) Genome Institute of Singapore (Singapore)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement: development
Action mechanism:
Disease:
Details: * On May 21, 2013, A*STAR’s Genome Institute of Singapore (GIS) has signed an agreement with QuantuMDx (QMDx), a UK-based biotech developing handheld diagnostics and whole genome sequencing devices. Under this collaboration, QMDx’s wholly owned Singapore-based subsidiary QMDx Asia and GIS will develop Asia-specific point-of-care genetic tests for use with Q-POC™, QMDx’s handheld point-of-care device. QMDx will commercialize the tests.
The first assay from the development pipeline will direct treatment of East Asian patients with kinase-driven cancers, such as chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small lung cancer (EGFR NSCLC). QMDx’s handheld, sample-to-result diagnostic device Q-POC™ will be used to rapidly test patients, in a cancer clinic or post surgery, for the presence of a BIM deletion polymorphism genetic mutation which GIS has shown causes a patient’s malignancy to be unresponsive to the standard Tyrosine Kinase Inhibitors (TKI) treatment regime. Q-POC™, currently at prototype stage, utilises novel sample preparation, extraction, amplification and a nanowire biosensor to detect DNA sequences of interest in under 15 minutes, from sample to result.
Financial terms:
Latest news:
